{
    "clinical_study": {
        "@rank": "109304", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1", 
                "description": "NW-3509a - 1mg or placebo"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "description": "NW-3509a 2mg or placebo"
            }, 
            {
                "arm_group_label": "Cohort 3", 
                "description": "NW-3509a 5mg or placebo"
            }, 
            {
                "arm_group_label": "Cohort 4", 
                "description": "NW-3509a 10 mg or placebo"
            }, 
            {
                "arm_group_label": "Cohort 5", 
                "description": "NW-3509a 20 mg or placebo"
            }
        ], 
        "biospec_descr": {
            "textblock": "PK specimens will be drawn to determine the maximum tolerated dose of NW-3509a in heathly\n      male volunteers"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "This is a prospective, 8-day, randomized, double-blind, placebo-controlled,\n      sequential-cohort study designed to evaluate the safety, tolerability, and MTD of single\n      escalating oral doses of NW-3509A in healthy male volunteers. Five independent cohorts of 12\n      volunteers each will participate in this study, with the first 9 volunteers in each cohort\n      to qualify being randomized to receive study medication and the remaining 3 to be used as\n      backups/ alternates. In each cohort, 6 subjects will be randomly assigned to receive\n      NW-3509A and 3 subjects will receive placebo."
        }, 
        "brief_title": "A Phase I- Sequential Cohort Dosing to Determine Maximum Tolerated Dose in Healthy Male Volunteers.", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Schizophrenia", 
        "condition_browse": {
            "mesh_term": "Schizophrenia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Demographics\n\n        Volunteers will meet the following demographic inclusion criteria:\n\n          1. Age - between 18 and 45 years of age, inclusive.\n\n          2. Sex - males.\n\n          3. The subject has a body weight of at least 45 kg and a body mass index of \u226430.\n\n             Procedural\n\n             Volunteers will meet the following procedural criteria:\n\n          4. They are cooperative, able to take oral medication, willing to complete all aspects\n             of the study, and capable of doing so.\n\n          5. They will be able to understand the instructions and fully participate.\n\n          6. They will have provided written informed consent prior to participating in the study.\n\n          7. The  subject  is  in  good  health  with  no  history  of  significant  medical\n             disease  as  determined  by  the investigator.\n\n        Exclusion Criteria:\n\n        The presence of any of the following will exclude a subject from study enrollment:\n\n        General Medical Status\n\n          1. An advanced, severe, or unstable disease of any type that may interfere with any of\n             the study evaluations, including any medical condition that could be expected to\n             progress, recur, or change to such an extent that it may bias the assessment of the\n             clinical or mental status of the volunteer to a significant degree or put the\n             volunteer at special risk (e.g., liver or kidney disease; malignancy);\n\n          2. A disability that may prevent the volunteer from completing all study requirements\n             (e.g., blindness, deafness, severe language difficulty);\n\n          3. A current diagnosis of active, uncontrolled peptic ulceration within the last year;\n\n          4. A current diagnosis of acute, severe, or unstable asthmatic condition.\n\n             Cardiovascular\n\n          5. A current diagnosis of severe or unstable cardiovascular disease;\n\n          6. A current diagnosis of sick-sinus syndrome or conduction deficits (e.g., sino-atrial\n             block (<0.22), second or third degree atrio-ventricular block);\n\n          7. Any history or current evidence of a cardiac illness as determined by the\n             investigator;\n\n          8. Any clinically significant ECG abnormality, including a disorder of rate, rhythm, or\n             conduction, or other morphological changes, or a QTcF interval (Fridericia's\n             correction formula) on the ECG >450 msec. The 12-lead ECG will be used for\n             determining the suitability of the subject for inclusion in the study (determined by\n             the investigator);\n\n          9. Vital signs (supine) outside the following ranges:\n\n               -  Systolic blood pressure below 100 or above 139 mmHg;\n\n               -  Diastolic blood pressure below 50 or above 89 mmHg;\n\n               -  Radial pulse below 50 or above 90 bpm.\n\n             CNS related\n\n         10. Any history or current diagnosis of any neurodegenerative illness;\n\n         11. History or current diagnosis of epilepsy or seizure disorder.\n\n             Psychiatric\n\n         12. Any past or current psychiatric illness (DSM-IV-TR Axis 1 diagnosis);\n\n         13. Subjects with current or past suicidal ideation.\n\n             Study-specific criteria\n\n         14. History of serious adverse reactions or hypersensitivity to any drug;\n\n         15. Presence or history of allergies requiring acute or chronic treatment (except\n             seasonal allergic rhinitis);\n\n         16. Alcohol or drug abuser; currently or at any time in the last 5 years;\n\n         17. Abnormal physical findings of clinical significance at the screening examination or\n             baseline that would interfere with the objectives of the study;\n\n         18. Need of any prescription medication within 14 days prior to the administration of the\n             study drug, and/or non-prescription medication within 7 days prior to the\n             administration of the drug;\n\n         19. Participation in  other  clinical  trials  during  the  last  2  months  in  which an\n              investigational  drug or  a commercially available drug was tested;\n\n         20. Loss of 500 ml or more of blood during the 3-month period before the study, e.g. as a\n             donor.\n\n         21. Existence of any surgical or medical condition which might interfere with the\n             absorption, distribution, metabolism or excretion of the study drug, i.e. impaired\n             renal or hepatic function, diabetes mellitus, cardiovascular abnormalities,\n             inflammatory bowel disease, chronic symptoms of pronounced constipation or diarrhea,\n             or conditions associated with total or partial obstruction of the urinary tract;\n\n         22. Symptoms of  a  significant  somatic  or  mental  illness in  the  four-week  period\n             preceding  study drug administration;\n\n         23. History of hepatitis B and/or C, and/or positive serology results, which indicate the\n             presence of hepatitis B and/or C (Hepatitis B surface antigen and/or antibody to\n             Hepatitis C);\n\n         24. Positive results from the HIV serology;\n\n         25. Positive results of the drug and alcohol tests at screening and/or check-in at the\n             unit;\n\n         26. Smoker; currently or at any time in the last 5 years;\n\n             Laboratory abnormalities\n\n         27. Clinically significant abnormalities in routine laboratory examinations (hematology;\n             blood chemistry, including electrolytes and liver and kidney function tests;\n             urinalysis), as determined by the Principal Investigator in consultation with the\n             Sponsor, at the screening evaluation;\n\n         28. Clinically important laboratory abnormalities in thyroid function tests at screening:\n\n             \u2022 TSH > 8.0 mU/L and/or Free T4 < 9 pmol/L;\n\n             Concomitant therapy\n\n         29. A known exaggerated pharmacological sensitivity or hypersensitivity to drugs similar\n             to NW-3509A. Possible examples are volunteers who have experienced hypersensitivity\n             reactions to sodium channel blockers;\n\n         30. Ingested any of the following substances:\n\n               -  An investigational drug during the past 2 months;\n\n               -  A drug or treatment known to cause major organ system toxicity during the past\n                  year;\n\n               -  Any prescription drug or OTC product if taken continuously (Medical Monitor from\n                  Newron should be contacted if the Investigator wants to include a volunteer who\n                  is taking an OTC product);\n\n               -  Alcohol intake should be limited to 2 drinks per day during the 2 weeks prior to\n                  dosing; alcohol consumption will be prohibited from 72 hours prior to\n                  admittance on Day -1 through to the final safety evaluations on Day 8.\n\n               -  Caffeine-containing products should be limited (equivalent of 2 cups of coffee\n                  per day) during the 2 weeks prior to dosing and through to the final safety\n                  evaluations on Day 8."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Healthy Male Vounteers"
            }
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01955564", 
            "org_study_id": "NW-3509A/001/I/2011"
        }, 
        "intervention": {
            "arm_group_label": [
                "Cohort 1", 
                "Cohort 2", 
                "Cohort 3", 
                "Cohort 4", 
                "Cohort 5"
            ], 
            "intervention_name": "NW-3509a", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 17, 2014", 
        "location": {
            "contact": {
                "email": "hannavoltattorni@cnstrial.com", 
                "last_name": "Hannah Voltattorni", 
                "phone": "562-304-1742"
            }, 
            "contact_backup": {
                "email": "annecabral@cnstrial.com", 
                "last_name": "Anne Cabral", 
                "phone": "562-304-1742"
            }, 
            "facility": {
                "address": {
                    "city": "Long Beach", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "90806"
                }, 
                "name": "Collaborative Neuroscience Network-Clinical Pharmacology Unit"
            }, 
            "investigator": {
                "last_name": "Mark Leibowitz, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "5", 
        "official_title": "A Phase I, Prospective, Randomized, Double-blind, Placebo-controlled, Sequential-cohort, Escalating, Single-dose Study Designed to Determine the Maximum Tolerated Oral Dose of NW-3509A in Healthy, Male Volunteers.", 
        "overall_contact": {
            "email": "markleibowitz@cnstrial.com", 
            "last_name": "Mark Leibowitz, MD", 
            "phone": "562-304-1750"
        }, 
        "overall_contact_backup": {
            "email": "msidlowski@clinirx.com", 
            "last_name": "Marian Sidlowski, MS", 
            "phone": "484-340-6189"
        }, 
        "overall_official": [
            {
                "affiliation": "Collaborative Neuroscience Network Phase I Unit", 
                "last_name": "Mark Leibowitz, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Newron Sweden AB", 
                "last_name": "Ravi Anand, MD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Cardiac monitoring of subjects includes ECG extractions, continuous Holter Monitoring, vitals signs, blood testing, SSRS (suicidality) performed,and adverse event assessment to be performed", 
                "measure": "Evaluate safety and tolerability and maximum tolerated dose of NW-3509a in Healthy Male Volunteers", 
                "safety_issue": "Yes", 
                "time_frame": "Day -1(predose) through Day 3 -Discharge)"
            }, 
            {
                "description": "Determine occurrence of any adverse events", 
                "measure": "Evaluate safety and tolerability and maximum tolerated dose of NW-3509a in Healthy Male Volunteers", 
                "safety_issue": "Yes", 
                "time_frame": "Day 5 phone contact"
            }, 
            {
                "description": "Assessment of any adverse events, laboratory tests, ECG and a physical/neurological examination. An assessment of suicidality (through performing a C-SSRS, since last visit).", 
                "measure": "Evaluate safety and tolerability and maximum tolerated dose of NW-3509a in Healthy Male Volunteers", 
                "safety_issue": "Yes", 
                "time_frame": "Day 8"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01955564"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "To determine the pharmacokinetics of NW-3509a at doses tested", 
            "safety_issue": "Yes", 
            "time_frame": "PK collected prior to dosing and through Day 3 of study"
        }, 
        "source": "Newron Sweden AB", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Newron Sweden AB", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "October 2013"
    }
}